ASH 2015: Updated Results of the Phase I/II GEN503 Study of Daratumumab in Multiple Myeloma

In a study update presented by Plesner et al at the 57th American Society of Hematology (ASH) Annual Meeting, daratumumab (Darzalex) was shown to be safe and effective in combination with lenalidomide (Revlimid) and dexamethasone in patients with relapsed/refractory multiple myeloma (Abstract 507).

 The ASCO Post